Rocket Pharmaceuticals (RCKT) Retained Earnings (2014 - 2026)

Rocket Pharmaceuticals has disclosed Retained Earnings across 13 years of filings, most recently posting -$1.5 billion for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$1.5 billion, down 16.32% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.5 billion (down 16.32% YoY), and the FY2025 annual result was -$31000.0, up 100.0% from the prior year.
• Retained Earnings came in at -$1.5 billion for Q1 2026 at Rocket Pharmaceuticals, down from -$31000.0 in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $319000.0 in Q4 2023 to a low of -$1.5 billion in Q1 2026.
• The 5-year median for Retained Earnings is -$534.9 million (2022), against an average of -$539.4 million.
• Across the five-year window, Retained Earnings surged 189.36% in 2023 and sank 948048.15% in 2025, its largest moves.
• Rocket Pharmaceuticals' Retained Earnings stood at -$357000.0 in 2022, then soared by 189.36% to $319000.0 in 2023, then tumbled by 381954.55% to -$1.2 billion in 2024, then soared by 100.0% to -$31000.0 in 2025, then tumbled by 4802587.1% to -$1.5 billion in 2026.
• The last three Retained Earnings figures came in at -$1.5 billion (Q1 2026), -$31000.0 (Q4 2025), and -$9000.0 (Q3 2025), per Business Quant data.